REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Clinical trials for REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral drug called onvansertib for people with rare, aggressive blood cancers that have come back or stopped responding to available treatments. The main goals are to find a safe dose and see if the drug can help control the disease. The stud…
Matched conditions: REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a new combination of two drugs, axatilimab and azacitidine, for people with advanced or hard-to-treat blood cancers. The first part of the study aims to find the safest and most effective dose. The second part will see how well the drug combination works to …
Matched conditions: REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Triple-Threat attack on tough blood cancers shows promise
Disease control Recruiting nowThis study is testing a new combination of three drugs—azacitidine, venetoclax, and gilteritinib—for adults with certain aggressive blood cancers that have returned or not responded to treatment. The main goals are to find the safest dose and see if adding gilteritinib helps pati…
Matched conditions: REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC